Most advanced vaccine candidates (MIP and VPM1002) shortlisted after detailed landscape analysis. Capacity building of 7 centers with 5 subcenters done for undertaking clinical trials. A Phase III prevention of disease vaccine trial with 2 lead TB vaccine candidates (Mw(MIP) and VPM1002) initiated we.f 15th July.
